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Abstract
Longitudinal targeted maximum likelihood estimation (LTMLE) has hardly ever been used to
estimate dynamic treatment effects in the context of time-dependent confounding affected by prior
treatment when faced with long follow-up times, multiple time-varying confounders, and complex as-
sociational relationships simultaneously. Reasons for this include the potential computational burden,
technical challenges, restricted modeling options for long follow-up times, and limited practical guid-
ance in the literature. However, LTMLE has desirable asymptotic properties, i.e. it is doubly robust,
and can yield valid inference when used in conjunction with machine learning. It also provides the ad-
vantage of easy-to-calculate analytic standard errors in contrast to its main competitor, the g-formula,
which requires bootstrapping. We use a topical and sophisticated question from HIV treatment re-
search to show that LTMLE can be used successfully in complex realistic settings and compare results
to competing estimators. Our example illustrates the following practical challenges common to many
epidemiological studies 1) long follow-up time (30 months), 2) gradually declining sample size 3) limited
support for some intervention rules of interest 4) a high-dimensional set of potential adjustment vari-
ables, increasing both the need and the challenge of integrating appropriate machine learning methods.
Our analyses, as well as simulations, shed new light on the application of LTMLE in complex and
realistic settings: we show that (i) LTMLE can yield stable and good estimates, even when confronted
with small samples and limited modeling options; (ii) machine learning utilized with a small set of
simple learners (if more complex ones can’t be fitted) can outperform a single, complex model, which
is tailored to incorporate prior clinical knowledge; (iii) performance can vary considerably depending
on interventions and their support in the data, and therefore critical quality checks should accompany
every LTMLE analysis. We provide guidance for the practical application of LTMLE.
1 Introduction
Causal quantities, such as the average treatment effect, causal odds ratio or causal risk ratio, can often be
estimated from observational data if assumptions about the data generating process are made and met.
In this context, Targeted Maximum Likelihood Estimation (TMLE) is one estimation option. Since the
mid 2000’s TMLE has been implemented successfully in numerous applications, initially for the effects of
treatments or exposures at a single time point [1, 2, 3, 4]. In recent years, an increasing body of work
has dealt with the application of TMLE in longitudinal settings [5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16].
Longitudinal targeted maximum likelihood estimation (LTMLE) requires the fitting of models for
the outcome, censoring, and treatment mechanisms, at each point in time. Alternative approaches in-
clude those based on estimating the treatment mechanism only (inverse probability of treatment weighted
approaches)][17], the iterated outcome regressions only (one form of g-computation)[18] or an outcome
regression combined with the conditional densities of the confounders (“traditional” parametric g com-
putation) [19]. LTMLE is a doubly robust methodology which means that the causal quantity of interest
is estimated consistently if either the iterated outcome regressions or the treatment and censoring mech-
anism are estimated consistently. Moreover, LTMLE allows analytic estimation of standard errors and
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confidence intervals, based on estimates of the influence curve, as opposed to the g-formula which makes
use of bootstrapping [20]. To increase the chances of correct model specification, the use of machine learn-
ing algorithms are typically recommended. LTMLE, like other double robust methods, has the advantage
over both inverse probability weighted and g-computation methods that it can more readily incorporate
machine learning methods while retaining valid statistical inference.
The current literature is somewhat limited with respect to understanding the implications of using
LTMLE for long follow-up times when dealing with small (or moderate) sample sizes and complex rela-
tionships among a multitude of confounders. Most studies to date were illustrative in nature and have
dealt with a small number of follow-up time points, i.e. two to nine [5, 6, 7, 8, 9, 11, 12, 13, 14, 16],
or large sample sizes [10, 14, 16], but to our knowledge never with small or moderate sample sizes and
long follow-up at the same time. In spite of LTMLE’s double robustness feature, consistent estimation of
both treatment and censoring mechanisms and outcome regressions, with reasonable rates of convergence,
is important to improve efficiency, reduce finite sample bias, and provide the basis for valid statistical
inference. A small sample may limit the application of data-adaptive approaches, such as additive models,
boosting, random forests, shrinkage estimators, support vector machines and others, because the selection
of tuning parameters and convergence of fitting algorithms may not work well, or not at all, under these
circumstances – particularly when confronted with multiple time-dependent confounders which influence
outcome and treatment non-linearly and in interaction with each other. Interestingly, many studies using
LTMLE make restricted use of machine learning algorithms [6, 7, 10, 15, 16], posing the question whether
this was done intentionally because of restricted sample size or computational limitations.
A common estimation approach for LTMLE requires model fitting on the subset of subjects who
follow the intervention of interest (and remain alive and uncensored). This may pose a problem if follow-
up time is long and therefore the sample size reduces gradually: under these circumstances it may no
longer be possible to successfully fit a multitude of learners which makes correct model specification more
challenging. There exist alternative estimation approaches [11], as well as other estimators, both of which
utilize the full sample; it remains however to be investigated how the performance of these estimators
differ in a finite sample.
For applying LTMLE in survival analyses, both the treatment and censoring mechanisms need to be
modeled; in fact, for T time points, the cumulative inverse probabilities of remaining uncensored and
following the intervention of interest, i.e. the product of T × 2 inverse probabilities, are part of the
weighted fitting procedure. Unstable weights, possibly dealt with by truncation of the probabilities on
which the weight calculation is based, could therefore emerge under long follow-up and non-ideal modeling
strategies. It remains unclear to what degree this is a threat to the successful implementation of LTMLE.
The present article is based on our motivating question outlined in the next section. To answer it,
one has to deal with long follow-up times, gradually reduced sample size (down to 10% of the original
sample size of 2604) and multiple time-dependent confounders. Clinical knowledge suggests that the
data-generating process is complex in the sense that modeling should go beyond standard regression
approaches. We investigate challenges and solutions to apply LTMLE in this setting, both by means of
simulations and data analyses. In particular, we try to answer the following questions: (i) is it feasible
to apply LTMLE in such a setting; (ii) if yes, will the complex setup reduce the applicability of super
learning and would this impact the success of LTMLE?; (iii) under such a challenging scenario, could
a manual implementation which is informed by prior clinical knowledge and not data-adaptive be more
successful than an automated LTMLE procedure?; (iv) how do long follow-up times, gradually reduced
sample size, and truncated inverse probabilities impact on LTMLE for different intervention mechanisms?
(v) what can be learned from these points that would benefit future analyses which attempt to apply
LTMLE in complex data settings.
We introduce the motivating question in Section 2, followed by the theoretical framework in Section 3.
After presenting our data analysis (Section 4) we discuss the implications of LTMLE in such a setting by
means of both practical considerations and simulated studies in the following two sections. We conclude
in Section 7.
2
2 Motivating Example
During the last decade the World Health Organization (WHO) updated their recommendations on the use
of antiretroviral drugs for treating and preventing HIV infection several times. In the past, antiretroviral
treatment (ART) was only given to a child if his/her measurements of CD4 lymphocytes fell below
a critical value or if a clinically severe event (such as tuberculosis or persistent diarrhoea) occurred.
Based on both increased knowledge from trials and causal modeling studies, as well as pragmatic and
programmatic considerations, these criteria have been gradually expanded to allow earlier treatment
initiation in children: ART has shown to be effective and to reduce mortality in infants and adults
[21, 22, 23], but concerns remain due to a potentially increased risk of toxicities, early development of
drug resistance, and limited future options for people who fail treatment. In late 2015, WHO decided to
recommend immediate treatment initiation in all children and adults.
It remains important to investigate the effect of different treatment initiation rules on mortality,
morbidity and child development outcomes; for example, because of possible unknown long-term treatment
effects and the increase in drug related toxicities. However given the shift in ART guidelines towards earlier
treatment initiation it is no longer ethically possible to conduct a trial which answers this question in
detail. Moreover, trials are often restricted by testing intervention mechanisms in idealized, non-realistic,
settings - for example by imposing regular medical visits and therefore attention which would not happen
in most public health programmes.
Thus, observational data can be used to obtain effect estimates to compare early versus delayed treat-
ment initiation rules. Methods such as inverse probability weighting of marginal structural models, the
g-computation formula, and longitudinal targeted maximum likelihood estimation can be used to obtain
results in complicated longitudinal settings where time-varying confounders affected by prior treatment
are present — such as, for example, CD4 count which influences both the probability of ART initiation
and outcome measures [24, 11].
Below we focus on children’s growth outcomes, measured by height-for-age z-scores, and explore the
effect of different treatment initiation criteria on it. We are particularly interested in whether strategies
that offer earlier treatment initiation are beneficial for children’s growth.
3 Methodological Framework
Consider n subjects studied at baseline (t = 0) and during discrete follow-up times (t = 1, . . . , T ) where
T defines the end of follow-up. Some subjects may be censored and not be followed until T . The
data for each time point t consists of the outcome Yt, an intervention variable At, q time-dependent
covariates Lt = {L1t , . . . , Lqt}, and a censoring indicator Ct. We assume this ordering to reflect the causal
ordering for a given time point t. Note that Lt may contain indicator variables which describe whether
Lst has been measured at time t or not, s ∈ {1, . . . , q}. Moreover, Lt may also include baseline variables
V = {L10, . . . , LqV0 } and can potentially contain variables which refer to the outcome variable before time
t, for instance Yt−1. The treatment and covariate history of an individual i up to and including time t
is represented as A¯t,i = (A0,i, . . . , At,i) and L¯
s
t,i = (L
s
0,i, . . . , L
s
t,i) respectively. Ct equals 1 if a subject
gets censored in the interval (t− 1, t], and 0 otherwise. Therefore, C¯t = 0 is the event that an individual
remains uncensored until time t. Further, let St,i be an indicator variable which is 1 if a patient i is still
alive at time t and 0 otherwise.
The counterfactual outcome Y a¯tt,i refers to the hypothetical outcome that would have been observed at
time t if subject i had received, possibly contrary to the fact, the treatment history A¯t,i = a¯t. Similarly,
La¯tt,i are the counterfactual covariates related to the intervention A¯t,i = a¯t. The above notation refers
to static treatment rules; a treatment rule may, however, depend on covariates, and in this case it is
called dynamic. A dynamic rule dt(L¯t, St) assigns treatment At,i ∈ {0, 1} as a function of the covariate
history L¯t,i, conditional on survival. The vector of decisions dt, t = 0, ..., T , is denoted as d¯T = d¯. The
notation A¯t = d¯ refers to the treatment history according to the rule d¯. The counterfactual outcome
related to a dynamic rule d¯ is Y d¯t,i, and the counterfactual covariates are L
d¯
t,i. In the remainder of this
paper we consider rules dt that assign At as a function of L¯t and set Ct deterministically to 0, conditional
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on survival.
Without loss of generalization we consider the expected value of Y at time T , under no censoring, for
a given treatment rule d¯, conditional on survival (under this rule) until at least the beginning of the time
interval (t− 1, t], to be the main quantity of interest, that is ψT = E(Y d¯T |Sd¯T−1 = 1). Secondary quantities
of interest are the expected values at different time points, i.e. ψt = E(Y d¯t |Sd¯t−1 = 1).
Below, in Sections 3.1, 3.2, and 3.3, we are going to introduce 3 estimators which are generally suitable
to estimate ψT . These estimators are further discussed in Section 3.4, and are implemented and compared
in both the data analysis (Section 4) and the simulation study (Section 6).
3.1 The (parametric) g-formula
One possibility to identify the quantity of interest is by using the (parametric) g-formula [19]:
ψT = E(Y d¯T |Sd¯T−1 = 1) =∫
l¯∈L¯t

E(YT |A¯T−1 = d¯T , L¯T = l¯T , ST−1 = 1)×
T∏
t=1
[
f(lt|A¯t−1 = d¯t−1, L¯t−1 = l¯t−1, St−1 = 1)×
P(St−1 = 1|A¯t−1 = d¯t−1, L¯t−1 = l¯t−1, St−2 = 1)
]
 d¯l (1)
For ordered Lt = {L1t , . . . , Lqt} we can write f(lt|A¯t−1 = d¯t−1, L¯t−1 = l¯t−1, St−1 = 1) in (1) as
q∏
s=1
f(lst |A¯t−1 = d¯t−1, L¯t−1 = l¯t−1, L1t = l1t , . . . , Ls−1t = ls−1t , St−1 = 1) . (2)
The above representation of the g-formula makes an implicit assumption about the time ordering of
the relevant variables. For example, for s = 3 we assume that the ordering is St−1 → L1t → L2t → L3t →
Y → A → C → St for ∀t, see Section 5.2 for more details on the chosen time ordering. We assume
time points to represent intervals and thus both covariates and a fatal event like death can potentially be
measured at the same time t.
The equality holds under several assumptions. One is consistency which says that the counterfactuals
equal the observed data under assignment to the treatment actually taken; more technically, Y d¯t = Y if
A¯t = d¯t and L¯
d¯t
t = L¯t if A¯t−1 = d¯t−1. Another assumption is (sequential) conditional exchangeability (or
no unmeasured confounding) which requires the counterfactual outcome under the assigned treatment rule
to be independent of the observed treatment assignment, given the observed past: Y d¯t
∐
At|L¯t, A¯t−1 for
∀A¯t = d¯t, L¯t = l¯t, t ∈ {0, . . . , T}. Positivity is the requirement that individuals have a positive probability
of continuing to receive treatment according to the assigned treatment rule, given that they have done so
thus far and irrespective of the covariate history: P (At = d¯t|L¯t = l¯t, A¯t−1 = d¯t−1) > 0 for ∀t, d¯t, l¯t with
P (L¯t = l¯t, A¯t−1 = d¯t−1) 6= 0. In our setting, all above definitions apply to the subset of survivors at time
t.
If we intervene upon censoring, e.g. we are interested in a treatment rule where all individuals remain
uncensored, the above assumptions (consistency, sequential conditional exchangeability, positivity) also
apply to Ct. An important consequence of this is that the censoring mechanism has to be non-informative
(i.e. censoring may not depend on unmeasured variables).
More comprehensive interpretations of the above assumptions can be found in [24, 25, 26, 27, 28] and
are discussed in Section 5 as well.
3.1.1 Practical implementation of the (parametric) g-formula:
the integral (1) can be approximated by means of simulation:
1. Estimate the conditional densities in (1) by means of suitable, possibly semi-parametric, regression
models. One requires models for the s time-varying confounders Lst , the outcome Yt, as well as the
the survival indicator St, for t = 1, . . . , T . Note that for this step some parametric assumptions
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are required, e.g. committing to a normal distribution of the residuals with homoscedastic variance
when using a linear (additive) model.
2. Choose an intervention rule d¯.
3. Simulate data for the chosen intervention rule forward in time based on the estimated conditional
distributions from Step 1. For example, for t = 0, the data relates to the observed data. Then, for
each t > 0, set At according to the treatment rule d¯ and make predictions based on the models fitted
an step 1 (L˜st , Y˜t, and S˜t ). Then, generate stochastic draws given the conditional distributions. For
instance, for a linear regression model M with outcome Lst , draw from a N(L˜st , σˆ2M) distribution.
This draw relates to the estimated counterfactual Lˆs,d¯t .
4. Steps 1 to 3 produce a counterfactual data set for d¯ : D = {Ad¯, Lˆd¯, Yˆ d¯, Sˆd¯}. Thus, ψˆT = 1n
∑
i∈S Yˆ
d¯
T,i,
S = {∀iwith ˆ¯Sd¯i = 0} , can be easily calculated from this data set.
5. Confidence intervals are then created by means of bootstrapping.
3.2 The sequential g-formula
The g-formula integrates out time-dependent confounders, which are affected by prior treatment – with
respect to their post intervention distribution. This can be interpreted as a standardization with respect
to them. The sequential g-formula, introduced below, shares the idea of standardization in the sense that
one sequentially marginalizes the distribution with respect to L given the intervention rule of interest. It
is just a re-expression of the traditional g-formula where integration with respect L is not needed [8, 12].
In general, using the iterative conditional expectation rule (together with the above stated assumptions of
sequential conditional exchangeability, consistency, positivity and time ordering Lt → At → Yt) it holds
that
E(Y d¯T ) = E(E( . . .E(E(YT |A¯T = d¯T , L¯T )|A¯T−1 = d¯T−1, L¯T−1 ) . . . |A¯0 = d0,L0 )|L0 ) . (3)
However, our target quantity is ψT , which is defined as the expected value of Y at time T , for a
given treatment rule d¯ and no censoring, conditional on all survivors. As noted above we further assume
a time-ordering of St−1 → L1t → L2t → L3t → Y → A → C → St. We show in Appendix A that the
sequential g-formula in this case equates to
ψT = E(Y d¯T |Sd¯T−1 = 1)
= E(E(E(...E(E(YT |AT−1 = d¯T−1, L¯T , ST−1 = 1)|AT−2 = d¯T−2, L¯T−1, ST−1 = 1)...|
ST−1 = 1,L0,A0 = d0)|ST−1 = 1,L0)|ST−1 = 1) . (4)
3.2.1 Practical implementation of the sequential g-formula:
using equation (4) the target parameter can be estimated as follows:
For t = T, ..., 0:
1. Use an appropriate model to estimate E(YT |A¯T−1 = d¯T−1, L¯T , ST−1 = 1). The model is fitted on all
subjects that are uncensored and alive (until T − 1). Note that the outcome refers to the measured
outcome for t = T and to the prediction (of the conditional outcome) from step 2 if t < T .
2. Now, plug in A¯t = d¯t based on rule d¯ and use the regression model from step 1 to predict Yt at time
t.
3. For t = 0 the estimate ψˆT is obtained by calculating the arithmetic mean of the predicted outcome
(of all survivors) from step 2.
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4. Confidence intervals can be obtained using bootstrapping (or equation (6) below, which however
may not yield nominal coverage).
Appendix C, which illustrates implementation details for the LTMLE estimator from Section 3.3, can
also be seen as a guideline to implement the sequential g-formula: omitting steps 3 and 5 from the code
yields the desired solution.
3.3 The LTMLE estimator
The LTMLE estimator is based on (3) and goes back to Bang and Robins [18] and Scharfstein et al. [29],
and has been incorporated into a more general doubly robust framework by van der Laan and Rubin [30]
and others. For our target parameter ψT the LTMLE framework can be applied as follows: estimate ψT
with the sequential g-formula, but with an additional targeted step for each t which enables doubly robust
inference with respect to ψT , the quantity of interest.
3.3.1 Practical implementation of the LTMLE estimator:
For t = T, ..., 0:
1. Use an appropriate regression model to estimate E(YT |A¯T−1 = d¯T−1, L¯T , ST−1 = 1). The model is
fitted on all subjects that are uncensored and alive (until T − 1). Note that the outcome refers to
the measured outcome for t = T and to the prediction (of the conditional outcome) from step 3d if
t < T . (“Q0 model”)
2. Now, plug in A¯t−1 = d¯t−1 based on rule d¯ and use the regression model from step 1 to predict the
outcome at time t.
3. To improve inference with respect to the target parameter ψt update the initial estimate of step 2
by means of the following regression:
a) the outcome refers again to the measured outcome for t = T and to the prediction from item 3d
if t < T .
b) the offset is the original predicted outcome from step 2.
c) the estimated “clever covariate” refers to the cumulative inverse treatment [j = 1] and censoring
probabilities [j = 2] (estimated with the “g-model”):
Hˆ(A¯, C¯, L¯)s =
t∏
s=0
I(A¯js = d¯s)
Pˆ(Ajs = d¯s|L¯s = l¯s, Ajs−1 = d¯s−1)
; j ∈ {1, 2} (5)
d) Predict the (updated) outcome, Y˜ d¯t , based on the model defined through 3a, 3b, and 3c.
This model is fitted and evaluated for all subjects that are uncensored, alive (until T−1), and follow
treatment rule A¯t = d¯t (“Q
1 model”). Alternatively, the same model can be fitted with Hˆ(A¯, C¯, L¯)s
as a weight rather than a covariate [8].
4. For t = 0 the estimate ψˆT is obtained by calculating the mean of the predicted outcome (of all
survivors) from step 3d.
5. Confidence intervals can, for example, be obtained using the vector of the estimated influence curve
[31] of ψT , which can be written as
ÎC(ψT ) =
{
T∑
s=1
Hˆ(A¯, C¯, L¯)s−1
[
Y˜ d¯s − Y˜ d¯s−1
]}
+ Y˜ d¯0 − ψˆT,TMLE (6)
An asymptotically normal 95% confidence interval is then given by[
ψˆTMLE ± 1.959964
√
V̂ar(ÎC)/n
]
.
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It has been shown that using the five steps above yields a doubly robust estimator of ψT [18]. Doubly
robust means that the estimator is consistent as long as either the outcome model[s] (step 1) or the treat-
ment model[s] (step 3c) are estimated consistently. If both are estimated consistently at reasonable rates,
the estimator is asymptotically efficient. This is essentially because step 3, in particular the construction
of the covariate in step 3c, guarantees that the estimating equation corresponding to the efficient influence
curve is solved, which in turn yields desirable (asymptotic) inferential properties. The interested reader
is referred to the appendix of van der Laan and Rose (2011) [20], or Schnitzer and Cefalu [32], for details
on how the influence curve relates to inference in targeted maximum likelihood estimation.
3.4 Inferential considerations for the three presented estimators
Each of the above introduced estimators requires the estimation of conditional expectations which can be
utilized with (parametric) regression models. Under the assumption that they are correctly specified this
approach is valid. In a complex longitudinal setting such as ours, model mis-specification is a concern,
and may yield a biased estimate of ψT .
An alternative to using regression models would be (supervised) machine learning, which is a loose
term in the statistical literature referring to both traditional and modern estimation techniques, such
as semi-parametric regression models, shrinkage estimators, boosting, random forests, support vector
machines, and others. For a given data set, and an a priori specified set of estimation techniques,
the method minimizing the expected prediction error (as estimated by k-fold cross validation) can be
chosen. As it is not clear beforehand which method this is, and whether a combination of learners might
perform even better than a single one, one may use super learning. Super learning, which is also known
as stacking [33], means considering a set of prediction algorithms (“learners”); Instead of choosing the
algorithm with the smallest cross validation error, super learning chooses a weighted linear combination
of different algorithms, that is the weighted combination which minimizes the k-fold cross validation error
(for a given loss function, e.g. quadratic loss). This combination is linear, the weights are non-negative
and sum up to one. This can be easily utilized with either quadratic programming or a non-negative least
squares estimation approach, and is implemented in the R-package SuperLearner [34]. It can be shown
that this weighted combination will perform at least as well as the best algorithm, if not better [35]. If
none of the specified algorithms is a correctly specified parameteric model, then the super learner will
perform asymptotically as well as the oracle selector (which chooses the best algorithm in the library),
otherwise it will achieve an almost parameteric rate of convergence (and will therefore perform reasonably
but will not be as good as the best candidate algorithm). For all methods a major advantage of using
super learning (rather than a single regression model) is that the probability of model mis-specification
is reduced because distributional assumptions are not needed and complex multivariate relationships can
potentially be represented by the weighted combination of (potentially simple) learners. However, i) good
prediction algorithms may still yield biased model estimates of the conditional expectations (in exchange
for reduced variance) and ii) cross validation evaluates the expected prediction error with respect to
the global fit of the conditional expectation, and not the scalar parameter ψT . TMLE incorporates the
targeting step towards ψT and can thus use super learning, whereas the (sequential) g-formula may not
necessarily benefit from it.
The successful use of super learning requires a good and broad selection of prediction algorithms, and
the ability to estimate these on the data. This may be challenging for longitudinal data with many time
points and small sample size, as in our data. Section 5.4 gives a thorough discussion on the challenges
and appropriate use of machine learning for data setups like ours.
4 Data Analysis
We study 2604 children aged 1-5, with complete baseline data, for t = 0, 1, 3, 6, 9, . . . , 30 months. The
follow-up time points refer to the intervals (0, 1.5), [1.5, 4.5), [4.5, 7.5), [7.5, 10.5), [10.5, 13.5), [13.5, 16.5),
[16.5, 19.5), [19.5, 22.5), [22.5, 25.5), [25.5, 28.5), [28.5, 31.5) months respectively. After 30 months of
follow-up 1421 children were still alive and in care. Follow-up measurements, if available, refer to mea-
surements closest to the middle of the interval. In our data Yt refers to height for age z-score (HAZ) at
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time t (i.e. measured during the interval (t − 1, t]). This growth outcome is of potential interest as the
PREDICT trial, conducted in children aged 1-12 years, showed better height gain for children who start
ART immediately [36, 37]. The binary treatment variable At refers to whether ART was taken at time t
or not. Similarly, Ct and St describe whether a patient was censored (administratively or due to loss to
follow-up), or died, at time t respectively. Children were defined as being lost to follow-up if at the time
of database closure they had no contact with their health care facility for at least 9 months since their
last recorded visit. Time-dependent confounders affected by prior treatment refer to Lt = (L
1
t , L
2
t , L
3
t )
which are CD4 count, CD4%, and weight for age z-score (WAZ) which is a proxy for WHO stage [38].
Similarly, we write L1mt , L
2m
t , L
3m
t for indicator variables which specify if L
s has been measured at time
t or not. They are needed to facilitate estimation step 3 for the g-formula. V = LV0 refers to baseline
values of CD4 count, CD4%, WAZ, HAZ as well as sex, age, year of treatment initiation and region. The
primary outcome is Y30 and therefore Yt, t < 30, could be regarded as additional confounder L
4
t . We
consider the following four interventions, two of them static, two dynamic:
d¯1t = {ct = 0; and at = 1 for ∀t
d¯2t (CD4 countt,CD4%t) =
{
ct = 0; and at = 1 if CD4 count
d¯
t < 750 or CD4%
d¯
t < 25%
ct = 0; and at = 0 otherwise
d¯3t (CD4 countt,CD4%t) =
{
ct = 0; and at = 1 if CD4 count
d¯
t < 350 or CD4%
d¯
t < 15%
ct = 0; and at = 0 otherwise
d¯4t = {ct = 0; and at = 0 for ∀t
The first intervention (d¯1t ) means immediate treatment initiation, the last one (d¯
4
t ) means no treatment
initiation, and interventions two and three (d¯2t , d¯
3
t ) mean deferring treatment until a particular CD4
threshold is reached.
We consider the mean HAZ at 30 months, under no censoring, for a given treatment rule d¯j , j = 1, ..., 4,
and for all survivors, to be the main quantity of interest, that is ψ30 = E(Y
d¯j30
30 |Sd¯
j
30
30 = 1). We estimate
ψ30 based on four approaches:
(i) using the g-formula as described in (1) with a manual implementation which includes prior clinical
prior knowledge (i.e. using only additive regression models)
(ii) using the sequential g-formula as described in (3), automated using the ltmle package in R [9, 39]
with a data adaptive estimation approach.
(iii) using TMLE as described in Section 3.3 with a manual implementation which includes prior clinical
knowledge (i.e. using only additive regression models)
(iv) using TMLE as described in Section 3.3 automated using the ltmle package in R [9, 39] with a data
adaptive estimation approach.
This choice essentially compares using standard software approaches (ltmle, existing and applicable super
learning wrappers) with a manual implementation which uses only one learner (additive models), however
one which is complex, not implemented in a wrapper, and incorporates prior clinical knowledge. Section
5.5 provides more details on the choice of these estimators.
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4.1 Model choice
The implementation details for both LTMLE estimators are given in appendices B and C, and are discussed
further in Section 5. Briefly, for the automated implementations, i.e. estimators (ii) and (iv), we use
the following specifications: first, we do not specify the regression models for outcome, treatment, and
censoring parametrically, but use super learning instead. The candidate learners were the arithmetic mean,
the full (generalized linear) regression model [GLM], GLM’s based on an EM-algorithm-Bayesian model
fitting, GLMs chosen by model selection with Akaikes Information Criterion [AIC], GLMs containing
interaction terms, as well as additive models – i.e. those learners which could be successfully fit on our
data.
Our manual implementation of the g-formula followed Schomaker et al. [37, Appendix]. Briefly, we
used semi-parametric additive linear and logistic regression models to model the conditional densities
in (1) and (2); To allow for flexible disease progression depending on how sick children are when they
present at their first visit, interactions of baseline characteristics (represented in categories) with all other
variables were added. Depending on the functional form of the covariates these interactions were either
linear or non-linear (using penalized splines). Model selection by means of generalized cross validation
was used to improve the bias-variance tradeoff in these models. All models implicitly assume that time-
dependent risk factors measured before or on time t− 2 do not predict the respective outcome. Note that
the same approach of model building was used for our manual LTMLE estimator (iii). Sections 5.3, 5.4,
and 5.5 give a thorough discussion of the issue of model choice.
4.2 LTMLE implementation
Both the automated and the manual implementation of the LTMLE algorithm do not use linear regression
models to model the outcome, HAZ; rather, the data are transformed to lie between [0, 1] and a Quasi-
binomial model ([40]) is used. This is the way the ltmle package deals with continuous outcomes with
the aim to improve stability, particularly in the context of (near) positivity violations [41].
The clever covariate as defined in step 3 in Section 3.3 is included in the regression model not as a
covariate, but as a weight [8]. This is another valid targeted maximum likelihood estimator, based on a
refined loss function (and parametric submodel), and can improve stability [42]. This approach is again
part of the ltmle implementation.
Moreover, the denominator of the clever covariate (5) is bounded in the sense that values < g are
truncated at g. The automated implementation uses the default of g = 0.01, the manual implementation
a stricter version of g = 0.05 to deal with variable inverse probabilities; see Section 5.7 for a thorough
discussion on truncation of the clever covariate.
4.3 Other details
Our automated implementation of the sequential g-formula, i.e. estimator (ii), follows the automated
implementation of LTMLE, except that step 3 in Section 3.3 is not part of the inference procedure.
All four methods use the square root of CD4 count to work with a more symmetric variable.
4.4 Results
Figure 1 summarizes the results of the analyses, i.e the point and interval estimates for ψ6, ψ12, ψ24, ψ30.
For immediate ART initiation, point estimates of our manual implementation of the g-formula deviated
from the other estimates by approximately -0.2 after 30 months (Figure 1, top left). The dynamic
intervention of starting ART if either CD4 count < 750 or CD4% < 25% produced similar estimates for
all methods, except for the manual implementation of LTMLE which produced slightly more optimistic
estimates than the other methods after 30 months of follow-up.
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For the second dynamic intervention (Figure 1, bottom left) estimates from the manual implemen-
tations (i.e. estimators (i) and (iii)) where generally lower than the estimates from the automated im-
plementations. One of the most interesting results can be seen for the intervention “no ART initiation”:
here, automated estimation via LTMLE deviated by approximately -0.2 from all other methods (Figure
1, bottom right).
For all results confidence intervals were widest for our manual implementation of LTMLE, followed
by our manual implementation of the g-formula. There is a tendency for all estimators to suggest better
outcomes with earlier treatment initiation; however, the automated implementations are not so clear
about this for the intervention that uses the 350/15% threshold. Also, the automated TMLE procedure
suggests more drastic consequences of withholding antiretroviral treatment (“never ART”) than the other
estimators.
Our manual implementations of the g-formula and TMLE suggest broadly similar growth differences
between the different intervention strategies as Schomaker et al. [37], who implemented a similar analysis
on a much bigger dataset using the g-formula with good performance under the natural course scenario
(see also Section 5.6), but with an emphasis on mortality estimates. Our automated LTMLE procedure
deviates from these results by estimating the 350/15% intervention more positive and the never ART rule
more negative.
For all interventions and time points, super learning made heavy use of additive models in the Q-
models (weights, averaged over time points, between 0.46 and 0.91), and moderate use in the g-models
(weights, averaged over time points, between 0.16 and 0.41). It is worth pointing out that for the g-models
a simple learner such as the arithmetic mean was important, with average weights between 0.19 and 0.57.
5 Challenges in Identifying the Causal Parameter of Interest in the
Data Analysis
5.1 Long follow-up and sample size
All 4 estimators under consideration require regression models (or data adaptive approaches) to be fitted
on all subjects who are alive and uncensored at time t. It is evident that the longer the follow-up, the
fewer subjects can be used to fit the respective models, e.g. after 30 months of follow-up only 1421
patients remain.
As we discuss below, this can be a problem as all estimators rely on correct model specifications and
with smaller sample sizes it may no longer be possible to use more complicated methods, such as additive
models with non-linear interactions or advanced machine learning algorithms. Moreover, this problem
can potentially become even more severe in step 3 of the presented LTMLE algorithm: here, the models
are estimated on the subset of patients alive, uncensored and following treatment A¯t = d¯t.
In our data, after 30 months of follow-up, we have 341 (13.1%) patients alive and uncensored following
rule d¯130, 360 (13.8%) patients alive and uncensored following rule d¯
2
30, 464 (17.8%) patients alive and
uncensored following rule d¯330, and 259 (9.9%) patients alive and uncensored following rule d¯
4
30. Note that
after 30 months of follow-up we have evaluated 3 confounders, the outcome, as well as treatment at 11
different time points. Together with the baseline confounders this makes about 60 covariates which are
potentially relevant to the respective regression models at time 30. With adding non-linear relationships,
for example via penalized splines, the number of parameters that need to be estimated can therefore
be close to n. The consequence is that complex estimation procedures, which may be needed for data
adaptive approaches, may either fail or yield unstable solutions.
5.2 The implicit structural causal assumptions
For both the g-formula and the LTMLE estimators we make implicit assumptions about the time-ordering
of the data. For our data analysis the assumptions can be visualized as follows:
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V L11 L
2
1 L
3
1 Y1 A1 C1 S1
... L130 L
2
30 L
3
30 Y30
Note that V includes Y0, and that we do not explicitly specify A0, C0, and S0 here, as by definition
everyone is uncensored, untreated and alive at t = 0. Equation (2) implies that the ordering of the time-
dependent confounders Lt can possibly affect the results of the g-formula: the confounder distribution
which comes last, i.e the one referring to L3t , can be informed by the other confounders measured at the
same time point, L1,2t , but not vice versa. While all factorizations of Lt are valid, they may yield somewhat
different answers in a finite sample. In our data, the obvious choice for L3 is WAZ, as it is a strong proxy
for disease severity, which in turn predicts mortality [38]. It is clear that g-formula analyses benefit from
sensitivity analyses with respect to the ordering of the time-dependent confounders. However, this may
be very time-consuming or even unfeasible given the additional burden of bootstrapping. For LTMLE
estimators the ordering of the Ls does not play a role, and neither is bootstrapping needed – which shows
the method’s benefits in this regard.
Each time point refers to an interval and different choices of the ordering of treatment, censoring,
confounder, and outcome distribution can be justified. Treatment decisions can potentially be informed
by lab measurements (L1, L2) and clinic measurements (L3, Y ) which we have acknowledged in our time
ordering. Since death and censoring can happen until the end of an interval, and a patient may still
experience measurements before, we assume S and C to be measured at the end.
If we assume time points referring to intervals, as in our data set and most observational data analyses,
time-ordering assumptions may not always be met exactly. While this point may not be of major practical
relevance, it has hardly ever been acknowledged in the literature and deserves more research. Being aware
of it can help making appropriate decisions in terms of data management.
5.3 Model selection in a structural model
The implicit ordering of variables as outlined above can be regarded as a structural model. This model
is guided by prior knowledge. In our data analysis it is clear that decisions of treatment assignment are
made based on CD4 count, CD4% and WHO stage, approximated by WAZ [38]. Therefore, the structure
in terms of inclusion and exclusion of relevant variables is clear. The conditional expectations which need
to be estimated for all three estimators should therefore, by definition, contain all specified variables from
a philosophical point of view. However, as discussed in Section 5.1, this may be practically unfeasible
because of reduced sample sizes for long follow-up times and many potential confounders. In this case,
there is no way around model selection.
It is well-known that model selection in regression models yields typically biased estimates, over-
confident confidence intervals, but possibly improved bias-variance tradeoff with respect to regression
parameters and prediction [43, 44]. However, this is not of major relevance here because we are interested
in making inference about ψ and not the regression parameters.
The traditional way to reduce the expected prediction error is using cross-validation [45]. LTMLE
estimators make (valid) use of the extended concept of super learning, as explained above. It is worth
highlighting that even after a prior decision on a pool of learners, model selection is needed, typically
for tuning parameters. For example, a shrinkage estimator, say LASSO, is based on decisions around
the number of possible tuning parameters and a criterion to choose it (e.g. generalized cross validation).
The uncertainty around tuning parameter selection is typically ignored [46] and is one reason why the
combination of the g-formula with data adaptive estimation can lead to invalid inference, i.e. confidence
intervals which don’t adhere to the nominal coverage level [47].
Note that the SuperLearner package makes assumptions about the choice of tuning parameters, which
– for a given data set – may not be ideal and would require modification.
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5.4 Machine learning
The successful use of super learning for LTMLE estimators has been shown repeatedly in the literature
[10, 20]. However, the problem for our motivating example is that particularly for longer follow-up times
most of the available machine learning algorithms failed. In fact, we were only successful in using the
learners described in Section 4. All other algorithms provided by the SuperLearner package failed. One
could argue that under such circumstances the use of super learning is limited, unless one is able to and
willing to write custom-made own wrappers.
Reasons for failure were manifold: (i) memory problems because of the use of complex fitting algo-
rithms in the context of large covariate data (ii) non-convergence of fitting algorithms because of p ≈ n
(iii) sparse covariate data (iv) un-identified problems of the fitting algorithm (v) inability to use existing
wrappers for Quasi-binomial model ([40], which are used in ltmle for bounded and transformed con-
tinuous outcomes) and (vi) others. Note that we need predictions from 3 prediction models/algorithms
(one in step 1 and two in step 3c) for 11 time points, and for 4 interventions. Each time we work with a
different subset of data with different covariate combinations. If problems occur for one model, potentially
because of the specific sub-sample of data, super learning can fail as a whole.
5.5 Non-linear interactions
A clinical hypothesis in our data is that patients who are sicker at presentation will have a different disease
trajectory from patients who are healthier at presentation. Children who arrive with severe disease will
not be able to recover as fast as healthy children and will also not be able to reach the same CD4 count
levels [37]. A model describing this relationship could be of the form
g(E(Yt)) = Xβ + f1(L
1
τ , L
2
τ ) + f2(L
1
τ , L
3
τ ) + f3(L
2
τ , L
3
τ ) τ ∈ {1, . . . , t}
where g(·) represents a link function (i.e. the identity link if Y refers to HAZ), Xβ refers to the parametric
part of the model (e.g. binary baseline variables), and fj are unspecified general smooth functions. Similar
models can be specified if Lst is the outcome or when t refers to lagged variables. The major point here is
that the above model is a generalized additive model in its wider sense [48]. No matter whether using the
g-formula or an LTMLE estimator it is important to deal with many multiple non-linear interactions at
the same time. The R library mgcv can fit models as specified above, and this is the reason why we use
them in our manual implementations, i.e. estimators (i) and (iii). Using additive models in this context
requires stepwise manual inclusion of non-linear interactions, if they improve the prediction error in terms
of generalized cross validation, because inclusion of all possible interactions will make the fitting process
too complex to converge and also results in models with too high variance.
Note that the automated estimation procedures (ii) and (iv) include the gam wrapper provided by
the SuperLearner package. However, this wrapper doesn’t use the mgcv implementation described above
but the one from package gam. While the latter has advantages in that it uses the simple backfit-
ting algorithm[49] for estimation, and could therefore be regarded as non-parametric rather than semi-
parametric, it lacks a flexible approach of dealing with interactions. Moreover, it does not use automated
smoothing parameter selection using cross validation but rather needs pre-specified knowledge for the
degrees of freedom of the model. Also, the wrapper implicitly assumes no interactions. This fact can
be irrelevant for super learning if enough learners are available, such that the combined weighted super
learner contains the predictive information related to the interactions; however, if the number of (pre-
implemented) learners that can be fitted is limited, as in our data analysis, the question arises whether
it may be preferable to proceed with a manual implementation rather than a restricted automated one.
This question will be answered later in this paper.
5.6 The natural course scenario (for the parametric g-formula)
Applying the g-formula assumes that the densities in (1) are estimated consistently. A necessary, but
not sufficient, condition for correct specification is that the g-formula re-produces the raw data (at least
approximately) if the treatment rule d¯ relates to the real treatment assignment process in the data.
More specifically, the “natural course scenario” evaluates the stochastic treatment rule where treatment
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assignment probabilities are estimated from P(At = at|A¯t−1 = a¯t−1, Yt = yt, L¯t = l¯t, C¯t−1 = 0, St−1 = 1)
and censoring is not intervened upon but modeled via P(Ct = 0|A¯t = a¯t, Yt = yt, L¯t = l¯t, C¯t−1 = 0, St−1 =
1). Then, ψˆt (and also
ˆ¯Ls,d¯
j
t ) produced by the g-formula can be compared to the real data and should
approximately match. Reporting the natural course scenario is a standard procedure in g-formula analyses
[21, 27, 37].
Figure 2 shows the natural course scenario for our data. The mean HAZ for both the raw data
(“observed data”) and the data produced by the g-formula (“no intervention”) are somewhat different.
The graph suggests that there might be model mis-specification as the estimates of the natural intervention
are lower than they should be. This may partly explain the results in Figure 1 (bottom left, top left).
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Figure 2: Natural course scenario
5.7 Inverse probabilities, truncation and positivity
As opposed to the g-formula, LTMLE estimators require models for the treatment and censoring mech-
anism. This mechanism is reflected in the clever covariate used in step 3c of the LTMLE algorithm.
While the LTMLE estimator is less sensitive than traditional inverse probability of treatment estimators
[47] it nevertheless includes inverse probability weights in its fitting process which may lead to increased
variance estimates when the weights become more variable [32].
For our motivating data example we have 22 treatment models relating to both the treatment and
censoring mechanism of 11 time points. Ideally the fitted cumulative inverse probabilities are not too
small, and values of the clever covariates are therefore not too large. Small estimated probabilities may
indicate near-positivity violations; i.e. if there are covariate strata where the (estimated) probability
of (not) receiving treatment is close to zero, for example when an extremely sick patient has not been
treated although this would have been expected according to the data of similar patients. Practically
positivity violations occur easily when dealing with many continuous confounders as in our data; but if
the data is still “rich” enough both the g-formula and the LTMLE estimator may be able to deal with it
and extrapolate based on the available data and estimated models [47].
One way to deal with small probabilities is to truncate them at a lower bound g. This reduces
14
variability and improves stability, however at the cost of bias if the truncation is too strong [41].
Table 1 summarizes mean clever covariates (i.e. cumulative inverse weights at time 30) for different
model specifications and interventions. Their mean should be about 1. More importantly, the percentage
of truncated probabilities (here, [cumulative] probabilities < 1% are truncated), should be as small as
possible.
Table 1: Mean clever covariate for LTMLE estimators (at t = 30) corresponding to different interventions
and model specifications. The percentage of truncated values refers to the proportion of probabilities <
1%.
mean clever covariate %truncated
Intervention N SL SL∗ GAM GLM SL SL∗ GAM GLM
no ART 259 3.32 5.74 8.64 10.33 5.3 13.5 73.4 100
350/15% 464 0.91 0.88 8.97 8.66 0 0 35.6 44.6
750/25% 360 0.87 0.56 4.91 2.00 0.3 0.3 19.7 10.6
immediate ART 341 0.82 0.42 4.28 0.53 0 0 16.7 0
Normal GLM’s which do not use any transformations or interactions and include covariate history up
to time t − 2 yield highly variable results, i.e. the mean clever covariate ranges from 0.53 to 10.33 and
between 0% and 100% of truncated observations. We know that these models are likely mis-specified, but
they yield clever covariates that shouldn’t cause a problem for the fitting process of step 3. Our man-
ual implementation of TMLE [estimator (iii)], which uses additive models with non-linear interactions
(“GAM”), leads to unstable weights with means that are far too high (> 4) and many small probabilities
which have been truncated. Using super learning (“SL”) yields good mean clever covariates for 3 inter-
ventions, but somewhat too high values for the intervention “no ART”, which is important to note given
the volatile results according to Figure 1. Adding an additional learner (“SL∗”), i.e. random forests, does
not improve the super learner as seen by the higher levels of truncation. This may be because this learner
has fitting problems for later follow-up points. This highlights that poor learners can decrease the quality
of the super learner in finite samples.
Table 2 lists point and interval estimates of LTMLE estimators (t = 30), as well as the corresponding
mean clever covariate and truncation percentages, for different model specifications for intervention d¯4.
Table 2: Point and interval estimates of LTMLE estimators (t = 30), as well as the corresponding mean
clever covariate, for different model specifications and truncation definitions. Results are provided for the
intervention “no ART”.
Estimates mean CC % truncated
LTMLE g=0.01 g=0.05 g=0.01 g=0.05 g=0.01 g=0.05
GLM -2.00 (-3.52; -0.47) -2.00 (-2.31; -1.68) 10.33 2.06 100 100
GAM -2.09 (-3.13; -1.06) -2.07 (-2.32; -1.83) 8.64 1.99 73.4 92.3
SL -2.25 (-2.42; -2.09) -2.20 (-2.31; -2.09) 3.32 1.96 5.3 38.1
SL∗ -2.12 (-2.21; -2.04) -2.12 (-2.20; -2.04) 5.74 2.42 13.5 69.2
It can be seen that model specification has a considerable impact on the results. While truncation
doesn’t effect the point estimates much, it is worth noting that an improved mean clever covariate comes
at the cost of truncation levels way above 35%, even with super learning. This raises the question whether
positivity violations are so severe that one wouldn’t trust any of the provided estimates for the fourth
intervention of interest. Interestingly, our manual implementation of LTMLE (using additive models)
yields estimates similar to the g-formula – in spite of the poor weights. This can be explained as follows:
the cumulative probabilities are so small that most of them get truncated and the clever covariate can
therefore hardly update the initial g-formula estimate in step 3 of the TMLE algorithm.
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6 Simulation Study
The following simulation is meant to investigate under which conditions effect identification with LTMLE
may be difficult, i.e. to what degree small samples, limited sets of learners, overuse of truncation and
intervention definitions may affect its performance. Based on our data analysis and the discussions in
Section 5 we generate longitudinal data (t = 0, 1, . . . , 12) for 3 time-dependent confounders, as well as
baseline data for 7 variables, using structural equations and the R-package simcausal [50]. Baseline data
resembles region, sex, age, CD4 count, CD4%, WAZ and HAZ respectively (V 1, V 2, V 3, L10, L
2
0, L
3
0, Y0).
Follow-up data refers to CD4 count, CD4%, WAZ and HAZ (L1t , L
2
t , L
3
t , Yt), as well as antiretroviral
treatment (At) and censoring (Ct). For simplicity, no deaths are assumed. The data generating mechanism
is described in detail in Appendix D. It leads to the following baseline values: region A = 75.5%; male
sex = 51.2%; mean age = 3.0 years; mean CD4 count = 672.5; mean CD4% = 15.5%; mean WAZ = -1.5;
mean HAZ = -2.5. At t = 12 the mean of CD4 count, CD4%, WAZ and HAZ are 1092, 27.2%, -0.8, -1.5
respectively. The target quantities ψj,t are defined as the expected value of Y at time t, t ∈ {6, 12}, under
no censoring, for a given treatment rule d¯j , where
d¯1t = {ct = 0; and at = 1 for ∀t
d¯2t =
{
ct = 0; and at = 1 if CD4 count
d¯2
t < 750 or CD4%
d¯2
t < 25% or WAZ
d¯2
t < −2
ct = 0; and at = 0 otherwise
d¯3t =
{
ct = 0; and at = 1 if CD4 count
d¯3
t < 350 or CD4%
d¯3
t < 15% or WAZ
d¯3
t < −2
ct = 0; and at = 0 otherwise
d¯4t = {ct = 0; and at = 0 for ∀t
The target parameters are ψ1,6 = −1.804, ψ2,6 = −1.850, ψ3,6 = −2.028, ψ4,6 = −2.452, ψ1,12 =
−1.029, ψ2,12 = −1.119, ψ3,12 = −1.466, and ψ4,12 = −2.447.
For R = 1000 simulation runs we estimate the above parameters using ltmle under the following
specifications: n ∈ {200, 600, 1000}; truncation levels g ∈ {0.01, 0.025, 0.04} and three different sets of
learners. Learner 1 consists of simple GLM’s, learner 2 adds both the arithmetic mean and GLM’s with
interactions to the set of learners, and learner 3 contains additionally GLM’s selected by AIC, standard
additive models (no interactions, package gam), as well as GLM’s based on an EM-algorithm-Bayesian
model fitting. For computational feasibility, all fitted models included only variables measured at time t,
t− 1, and 0 – in line with the data generating process.
The average useable size of the sample at the end of follow-up (i.e. excluding censored patients and
only including those who followed the respective treatment rule) varied between 39 (intervention d¯4) and
79 (intervention d¯2) for a baseline sample size of 200; between 116 (intervention d¯4) and 238 (intervention
d¯2) for a baseline sample size of 600; and between 190 (intervention d¯4) and 396 (intervention d¯2) for a
baseline sample size of 1000.
After 12 months of follow-up, for all interventions super learning (for learner 3) made heavy use of
additive models when estimating the Q-model: the respective super learner weight, averaged over time
and simulation runs, was always greater than 0.73. The g-models made particular use of GLM’s selected
by AIC.
Figure 3 shows the estimated bias and coverage probability, for different truncation levels, interven-
tions, learner sets, and sample sizes.
One can see that the bias varies substantially with respect to the chosen intervention. Interestingly
the interventions with the biggest data support (usable sample size) and with least data support, d¯4 and
d¯2, have the highest bias, showing that neither sample size nor type of intervention (static/dynamic)
offers a reasonable guideline to judge the quality of the estimated target quantity. Those interventions
with high bias have, obviously, also a poorer coverage.
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Figure 3: Estimated bias and coverage probability, at t = 12, for different truncation levels, interventions,
learner sets, and sample sizes.
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In this particular simulation setup the level of truncation hardly affects the results. There are gains
with a greater sample size, as one would expect; it is however worth pointing out that even with small
sample sizes results are relatively stable and good.
Of course, learner 3, with the biggest set of learners, typically performs best. Surprisingly the other
two learners also yield good results – which is encouraging given that the data-generating process contains
interactions and non-linear associations as well, and this isn’t specifically modeled by learner set 1 and
learner set 2.
Since in the simulation the data-generating process is known, we can estimate P (At = d¯t|L¯t =
l¯t, A¯t−1 = d¯t−1), i.e the probability of continuing to receive treatment according to the assigned treatment
rule, given that a patient has received treatment so far and irrespective of the covariate history. That is,
we can look at the indicator variable whether a patient has been treated according to the rule of interest at
each time point t, or not, given the past covariates and conditional on those which were treated according
to the rule at t− 1. If a substantial proportion of subjects have very small cumulative probabilities, then
this could be a sign of positivity violations. Table 3 lists the summaries of the cumulative probabilities.
Table 3: Proportion of cumulative probabilities of continuing to receive treatment according to the as-
signed treatment rule (given that this has been done so far and irrespective of the covariate history)
which are smaller than 0.01. The numbers are calculated based on the data-generating process in the
simulation, and are estimated from the data set as well, and for both at the end of follow-up.
d¯1t d¯
2
t d¯
3
t d¯
4
t
simulation 0.1% 0.3% 0.2% 0.8%
data 0% 0.8% 0.4% 1.9%
The table clearly shows that the highest proportion of small cumulative probabilities is found for the
second and fourth intervention, i.e. those interventions which performed worst in the simulations. This
highlights the fact that interventions need data support to meet the positivity assumption. In general
this can be also estimated in a data analysis, for a given estimation technique. When using a standard
logistic regression model we obtain the highest proportion of small cumulative probabilities for the fourth
intervention, i.e. the intervention that was most volatile in the data analysis. We suggest that in addition
to summaries of the clever covariates and percentage of truncated values, the data support for each
intervention, as presented in Table 3 should also serve as a diagnostic tool in LTMLE analyses.
7 Conclusions
To our knowledge this is the first successful implementation of LTMLE for a data set with > 10 follow-up
times and at least 3 time-dependent confounders (which are affected by prior treatment). Moreover, our
data analysis was based on a realistic data set relevant to public health policy making. Large longitudinal
data sets require specific care when using LTMLE: we have shown that long follow-up may come with
sample sizes that are small compared to the number of parameters that need to be fitted for machine
learning algorithms, including semi-parametric regression models. This can yield instabilities, memory
problems and identifiability problems that need to be addressed.
We have argued that there is practically no way around model selection in causal inference with both
the g-formula and LTMLE, despite the implicit assumption that some of the included confounders from
the structural causal model are irrelevant. This is because the causal parameter of interest can be best
identified with good predictions coming from an optimal bias-variance tradeoff. This model selection
process could incorporate clinical knowledge. We have included non-linear interactions using additive
model to address such hypotheses. While this may have potential benefits for the g-formula, our LTMLE
estimator could not be improved by such a strategy. In fact, a small super learner, with few algorithms,
led to more reliable and precise results.
Ideally large longitudinal causal analyses are best analyzed by several methods. If the results match,
then this is perfect. If not, diagnostics such as clever covariate and truncation summaries for LTMLE, or
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the natural course scenario for the g-formula are indispensable. Our analyses have shown that neither a
good natural course scenario for the g-formula nor considerations of sample size and type of intervention
(static/dynamic) offers a reasonable guideline to judge the quality of the estimated target quantity; what
matters is the support in the data for the intervention rule of interest: high levels of truncation and
small cumulative probabilties to continue to follow the rule of interest are always a sign of problems,
likely due to positivity violations or poor modeling strategies. They can be addressed by an increase
of appropriate learners, sometimes even if they are simple, or – less preferably – a change in the target
quantity. Whatever the methodological choices are, it remains important to consider the substantive
question at hand as well; for example, in our analysis, the most conservative estimates are provided by
the g-formula, and a clinician may prefer to base her/his decisions on these estimates if the diagnostics
for the method are acceptable.
We conclude the following with respect to the questions posed in the introduction:
• it is feasible to implement LTMLE in complex settings with long follow-up times, small sample size,
multiple time-dependent confounders, and dynamic interventions.
• as seen in both the data analysis and the simulations, LTMLE can be successful even when con-
fronted with limited modeling options, for example by a limited number of applicable learners when
using super learning. Nevertheless, it would be beneficial to have more learners available that work
with existing software packages and are computationally feasible in settings with long follow-up and
therefore multiple variables. We have made first attempts to address this issue available [51]; and
researchers with advanced programming capacities are advised to implement their own custom-made
wrappers, tailored to their own analysis of interest, if possible.
• in our setting we couldn’t find strong evidence that a flexible additive model, informed by prior
clinical knowledge, possibly in conjunction with competing estimators such as the g-formula, may
perform better than an automated LTMLE procedure with a limited set of learners.
• in the settings studied, a reduced sample size or truncation of inverse probabilities didn’t have a
major impact on the results; but it could be clearly seen that different interventions may have
different support in the data and that the success of estimators such as LTMLE also varied with
respect to the chosen intervention. This highlights the need to develop more diagnostic tools to di-
agnose practical positivity violations in the data. Reporting the percentage of truncated cumulative
inverse probabilities, summaries of the clever covariates and the data support for each intervention
(see Section 6) is highly recommended; but more research and guidance in this respect is needed.
A Identification of our causal parameter of interest
We consider time-ordered data as discussed in Section 3. In general, we assume St−1 → L1t → L2t →
L3t → Y → A → C → St, and for t = 0 we can write V→ Y0︸ ︷︷ ︸
L0
→ A0 → C0︸ ︷︷ ︸
A0
→ S0 → L1 → Y1, taking
into account baseline variables. Note that A0 and C0 are 0 and ‘uncensored’ for everyone by definition
and we don’t intervene upon them, and thus L1 could be considered as baseline as well. However, for
the general case, we show the identification of the causal parameter for the two time points t = 0, 1, then
t = t∗, t∗ − 1, and then infer to the sequence t = 0, 1, ..., T . The assumptions and definitions used are
the rule of iterated nested expectations (“IE”), consistency (“cons.”), and exchangeability (“exch.”) as
defined in Section 3.
(i) for t = 0, 1 it holds that
E(Y d01 |S0 = 1) IE= E(E(Y d01 |S0 = 1,L0)|S0 = 1)
IE
= E(E(E(Y d01 |S0 = 1,L0,A0)|S0 = 1,L0)|S0 = 1)
exch.
= E(E(E(Y d01 |S0 = 1,L0,A0 = d0)|S0 = 1,L0)|S0 = 1)
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IE
= E(E(E(E(Y d01 |S0 = 1,L0,L1,A0 = d0)|S0 = 1,L0,A0 = d0)|S0 = 1,L0)|S0 = 1))
cons.
= E(E(E(E(Y1|S0 = 1, L¯1,A0 = d0)|S0 = 1,L0,A0 = d0)|S0 = 1,L0)|S0 = 1))
(ii) for t = t∗, t∗ − 1 it holds that
E(Y d¯t∗−1t∗ |St∗−1 = 1) IE= E(E(Y d¯t∗−1t∗ |St∗−1 = 1,Lt∗−1)|St∗−1 = 1)
IE
= E(E(E(Y d¯t∗−1t∗ |St∗−1 = 1,Lt∗−1,At∗−1)|St∗−1 = 1,Lt∗−1)|St∗−1 = 1)
exch.
= E(E(E(Y d¯t∗−1t∗ |St∗−1 = 1,Lt∗−1,At∗−1 = d¯t∗−1)|St∗−1 = 1,Lt∗−1)|St∗−1 = 1)
IE
= E(E(E(E(Y d¯t∗−1t∗ |St∗−1 = 1,Lt∗−1,Lt∗ ,At∗−1 = d¯t∗−1)|St∗−1 = 1,Lt∗−1,
At∗−1 = d¯t∗−1)|St∗−1 = 1,Lt∗−1)|St∗−1 = 1))
cons.
= E(E(E(E(Yt∗ |St∗−1 = 1, L¯t∗ ,At∗−1 = d¯t∗−1)|
St∗−1 = 1,Lt∗−1,At∗−1 = d¯t∗−1)|St∗−1 = 1,Lt∗−1)|St∗−1 = 1))
(iii) Therefore, by induction, a time-sequence t = 0, ..., T , and for any general rule d¯, it follows that
ψT = E(Y d¯T |Sd¯T−1 = 1)
= E(E(E(...E(E(YT |AT−1 = d¯T−1, L¯T , ST−1 = 1)|AT−2 = d¯T−2, L¯T−1, ST−1 = 1)...|
ST−1 = 1,L0,A0 = d0)|ST−1 = 1,L0)|ST−1 = 1) .
B R code for automated estimation of Ψ6 with ltmle
To use the ltmle function from the package ltmle, one needs to provide the data in wide format. Below
we show 5 patients of our data set, where b1, b2, b3, b4 refer to the baseline values of
√
CD4 count, CD4%,
WAZ, and HAZ. Variable names ending with “.t” refer to measurements at time t. A.0 and C.0 are not
needed and reported as by definition everyone is ART-naive and uncensored at baseline. The variable
‘dead.at’ indicates the time interval in which a person died (and is 33 if the person didn’t die within the
first 30 months of follow-up). The choice of the data structure in terms of the ordering of the variables is
discussed in Section 5.2.
gender age_fv region2 b1 b2 b3 b4 cd4a_cf.1 cd4p_cf.1 wfa_cf.1 hfa_cf.1
1 1 4.752909 2 23.87467 15 -0.37 -0.30 23.87467 15 -0.37 -0.30
2 1 2.450377 2 26.98148 14 -0.81 -2.52 26.98148 14 -0.81 -2.52
3 1 2.318960 2 35.66511 14 -2.19 -3.13 35.66511 14 -2.19 -3.13
4 1 2.275154 2 34.46738 13 -2.13 -2.42 34.46738 13 -2.29 -2.38
5 1 2.091718 2 15.26434 6 -1.85 -1.62 15.26434 6 -2.02 -1.92
ART.1 censored.1 cd4a_cf.3 cd4p_cf.3 wfa_cf.3 hfa_cf.3 ART.3 censored.3 cd4a_cf.6
1 0 uncensored 23.87467 15 -0.50 -0.53 1 uncensored 23.87467
2 0 uncensored 26.98148 14 -1.30 -2.20 1 uncensored 26.98148
3 0 uncensored 35.66511 14 -2.54 -3.08 1 uncensored 35.66511
4 1 uncensored 34.46738 13 -2.41 -2.28 1 uncensored 36.63332
5 1 uncensored 15.26434 6 -2.14 -2.13 1 uncensored 22.40536
cd4p_cf.6 wfa_cf.6 hfa_cf.6 dead.at
1 15 -0.50 -0.53 33
2 14 -1.36 -1.99 33
3 14 -2.72 -3.36 33
4 17 -2.41 -2.28 33
5 21 -1.88 -1.34 33
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Before applying the ltmle command we need to define the intervention matrix. For a static interven-
tion, this could just be a vector such as c(0, 0, 0), but needs to be a matrix for dynamic interventions as
shown below. For illustrative purposes we use the intervention d¯2: “starting ART if either CD4 count
< 750 or CD4% < 25%” below. We also need to define the libraries used for the super learner, see Section
5.4 for more details.
# Define Intervention: start ART if CD4 count < 750 or CD4% < 25%
cd4_750.1 <- (mydata_wide$cd4a_cf.1 < sqrt(750) | mydata_wide$cd4p_cf.1 < 25)
cd4_750.3 <- (mydata_wide$cd4a_cf.3 < sqrt(750) | mydata_wide$cd4p_cf.3 < 25) | cd4_750.1
cd4_750.6 <- (mydata_wide$cd4a_cf.6 < sqrt(750) | mydata_wide$cd4p_cf.6 < 25) | cd4_750.3
abar750 <- as.matrix(cbind(cd4_750.1,cd4_750.3,cd4_750.6))
abar750[is.na(abar750)] <- 0
# Define collection of estimation methods to be used by SuperLearner
mylibrary <- list(Q=c("SL.mean","SL.glm","SL.stepAIC","SL.step.interaction","SL.gam","SL.bayesglm"),
g=c("SL.mean","SL.glm","SL.stepAIC","SL.gam","SL.bayesglm"))
Following (4), Ψ6 can be estimated easily on the data of survivors, as follows:
ltmle(mydata_wide[dead.at>=6,],
Anodes=c("ART.1","ART.3","ART.6"),
Cnodes=c("censored.1","censored.3","censored.6"),
Lnodes=c("cd4a_cf.1","cd4p_cf.1","wfa_cf.1","cd4a_cf.3","cd4p_cf.3","wfa_cf.3",
"cd4a_cf.6","cd4p_cf.6","wfa_cf.6"),
Ynodes=c("hfa_cf.1","hfa_cf.3","hfa_cf.6"), Yrange=c(-15,15),
Qform=NULL, gform=NULL, deterministic.g.function=MaintainTreatment, abar=abar750[dead.at>=6,],
SL.library=mylibrary, estimate.time=T, variance.method="ic", gbounds = c(0.01, 1)))
Note that Anodes, Lnodes, Cnodes, Ynodes refer to the treatment, censoring, covariate, and out-
come data respectively. By specifying a SL.library, and leaving the arguments for model formulae
(Qform, gform) empty, model specification is done by super learning. Yrange=c(-15,15) ensures that
the outcome is bounded (i.e. absolute z-scores greater than 15 are regarded to be impossible).
C R code for manual LTMLE estimation of Ψ6
The below implementation has been designed to be able to exactly reproduce the steps of the ltmle
command; but to adhere to the framework and notation of Section 3 at the same time. As noted in the
manuscript, we work with a transformed outcome and quasi-binomial models as ltmle does. We also add
the clever covariate as weights, as ltmle does. Furthermore, we use additive models based on the package
mgcv for model fitting. For comparing the manual and automated implementation, one could simply
use simple GLMs (no super learning) and specify the model form in the Qform and gform arguments.
The below code to truncate weights and to calculate confidence intervals is used later on in the main code.
gbounds <- function(x,bounds=c(0.05,1)){
x[x<min(bounds)] <- min(bounds)
x[x>max(bounds)] <- max(bounds)
return(x)
}
CI <- function(est,infcurv){
n <- length(infcurv)
ciwidth <- 1.959964 * sd(infcurv)/sqrt(n)
CI <- c(est-ciwidth, est+ciwidth)
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return(CI)
}
library(mgcv)
To estimate ψ6 we need to do the following:
# Data of survivors
mydata_wide6 <- mydata_wide[dead.at>=6,]
attach(mydata_wide6)
# Already prepare step 3c: fit treatment and censoring models
m1_c <- mgcv::gam(I(censored.1=="censored") ~ age_fv + s(b2) + s(b3) + s(b4), family=binomial)
m3_c <- mgcv::gam(I(censored.3=="censored") ~ gender + s(age_fv) + wfa_cf.1
+ s(I((hfa_cf.1 +15)/30)), family=quasibinomial)
m6_c <- mgcv::gam(I(censored.3=="censored") ~ s(b4) + s(wfa_cf.3) + I((hfa_cf.3 +15)/30),
family=quasibinomial)
m1_a <- mgcv::gam(ART.1 ~ s(cd4a_cf.1) + s(cd4p_cf.1) + s(wfa_cf.1) + s(b1) + s(b2) + s(b3),
data=mydata_wide6, family=binomial)
m3_a <- mgcv::gam(ART.3 ~ s(cd4p_cf.3) + s(wfa_cf.3) + s(cd4a_cf.1) + s(cd4p_cf.1) + s(b1) +
s(b2) + s(b3) + age_fv,
data=mydata_wide6[censored.1==1,], family=quasibinomial)
m6_a <- mgcv::gam(ART.6 ~ s(cd4a_cf.6) + s(cd4p_cf.6) + s(wfa_cf.6) + s(cd4p_cf.3) + s(cd4a_cf.3)
+ s(b3) + age_fv, data=mydata_wide6[censored.3==1,],family=quasibinomial)
# Already prepare step 3c: define subsets of patients uncensored and following the treatment rule
subset1 <- censored.1=="uncensored" & ART.1==abar[dead.at>=6,1]
subset3 <- censored.1=="uncensored" & ART.1==abar[dead.at>=6,1] & censored.3=="uncensored" &
ART.3==abar[dead.at>=6,2]
subset6 <- censored.1=="uncensored" & ART.1==abar[dead.at>=6,1] & censored.3=="uncensored" &
ART.3==abar[dead.at>=6,2] & censored.6=="uncensored" & ART.6==abar[dead.at>=6,3]
# Still prepare data for step 3c: calculate the cumulative treatment and censoring probabilites;
# also: apply cutoff at 0.05, i.e. probabilities <0.05 are defined as 0.05 -> clever covariate <= 20
p1a <- gbounds((ART.1 == 1)*predict(m1_a, type="response", newdata=mydata_wide6) +
(ART.1 == 0)*(1 - predict(m1_a, type="response", newdata=mydata_wide6)))
p3a <- gbounds((ART.3 == 1)*predict(m3_a, type="response", newdata=mydata_wide6) +
(ART.3 == 0)*(1 - predict(m3_a, type="response", newdata=mydata_wide6)))
p6a <- gbounds((ART.6 == 1)*predict(m6_a, type="response", newdata=mydata_wide6) +
(ART.6 == 0)*(1 - predict(m6_a, type="response", newdata=mydata_wide6)))
p1c <- gbounds((censored.1 == "censored")*predict(m1_c, type="response", newdata=mydata_wide6)+
(censored.1 == "uncensored")*(1 - predict(m1_c, type="response",newdata=mydata_wide6)))
p3c <- gbounds((censored.3 == "censored")*predict(m3_c, type="response", newdata=mydata_wide6)+
(censored.3 == "uncensored")*(1 - predict(m3_c, type="response",newdata=mydata_wide6)))
p6c <- gbounds((censored.6 == "censored")*predict(m6_c, type="response", newdata=mydata_wide6)+
(censored.6 == "uncensored")*(1 - predict(m6_c, type="response",newdata=mydata_wide6)))
# Still prepare data for step 3c: calculate clever covariate (=0 [weight 0] for those excluded)
mydata_wide6$cc1 <- 0
mydata_wide6$cc3 <- 0
mydata_wide6$cc6 <- 0
mydata_wide6$cc1[subset1] <- (1/(gbounds(p1a*p1c)))[subset1]
mydata_wide6$cc3[subset3] <- (1/(gbounds(p1a*p1c*p3a*p3c)))[subset3]
mydata_wide6$cc6[subset6] <- (1/(gbounds(p1a*p1c*p3a*p3c*p6a*p6c)))[subset6]
# Prepare for step 2: Define Intervention
newdata_wide6 <- mydata_wide6
newdata_wide6$ART.1 <- abar[dead.at>=6,1]
newdata_wide6$ART.3 <- abar[dead.at>=6,2]
newdata_wide6$ART.6 <- abar[dead.at>=6,3]
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### LTMLE estimation ####
# time point 6: start to calculate innermost expectation
m6_y <- mgcv::gam(I((hfa_cf.6 +15)/30) ~ s(age_fv) + s(b2) + s(b3) + s(b4) + ART.1 + s(cd4p_cf.3)
+ s(wfa_cf.3, by=b3) + s(I((hfa_cf.3 +15)/30)), data=mydata_wide6[censored.3==
"uncensored" & censored.1=="uncensored",], family=quasibinomial) # STEP 1
mydata_wide$ov6 <- predict(m6_y, newdata=newdata_wide6,type="response") # STEP 2
Qk6 <- glm("I((hfa_cf.6 +15)/30)~ 1 + offset(qlogis(ov6)) ", data=mydata_wide6, weights=cc6,
family = quasibinomial) # STEP 3a-c
mydata_wide$y3.Q <- predict(Qk6, type="response",newdata=mydata_wide6) # STEP 3d
# time point 3
m3_y <- mgcv::gam(y3.Q ~ (age_fv) + s(b3) + s(b4) + ART.1 + s(wfa_cf.1,by=b3)
+ s(I((hfa_cf.1 +15)/30),by=b3), data=mydata_wide6[censored.1=="uncensored",],
family=quasibinomial) # STEP 1
mydata_wide$ov3 <- predict(m3_y, newdata=newdata_wide6,type="response") # STEP 2
Qk3 <- glm("y3.Q ~ 1 + offset(qlogis(ov3)) ", data=mydata_wide6, weights=cc3, # STEP 3a-c
family = quasibinomial)
mydata_wide$y1.Q <- predict(Qk3, type="response",newdata=mydata_wide6) # STEP 3d
# time point 1+0: calculate final TMLE estimate
# (as everything before ART.1/hfa_cf.1 is essentially baseline due to no prior intervention)
est_ltmle.6 <- mean(mydata_wide$y1.Q)*30-15 # STEP 4
# Confidence Interval: calculate IC and set HAZ=0 if unmeasured at time t # Step 5
mydata_wide6$Y <- (mydata_wide6$hfa_cf.6+15)/30
mydata_wide6$Y[is.na(mydata_wide6$Y)]<-0
mydata_wide6$y3.Q[is.na(mydata_wide6$y3.Q)]<-0
IC <- mydata_wide6$cc3*(mydata_wide6$Y-mydata_wide6$y3.Q) + mydata_wide6$cc1*
(mydata_wide6$y3.Q-mydata_wide6$y1.Q) + mydata_wide6$y1.Q-mean(mydata_wide6$y1.Q)
IC <- IC*30-15
CI(est_ltmle.6,IC) # Final Confidence Interval
D Data generating process in the simulation study
Both baseline data (t = 0) and follow-up data (t = 1, . . . , 12) were created using structural equations
using the R-package simcausal [50]. The below listed distributions, listed in temporal order, describe
the data-generating process. Baseline data refers to region, sex, age, CD4 count, CD4%, WAZ and HAZ
respectively (V 1, V 2, V 3, L10, L
2
0, L
3
0, Y0). Follow-up data refers to CD4 count, CD4%, WAZ and HAZ
(L1t , L
2
t , L
3
t , Yt), as well as a treatment (At) and censoring (Ct) indicator. In addition to Bernoulli (B),
uniform (U) and normal (N) distributions, we also use truncated normal distributions which are denoted
by N[a,b] where a and b are the truncation levels. Values which are smaller a are replaced by a random
draw from a U(a1, a2) distribution and values greater than b are drawn from a U(b1, b2) distribution. Val-
ues for (a1, a2, b1, b2) are (0, 50, 5000, 10000) for L
1, (0.03,0.09,0.7,0.8) for L2, and (−10, 3, 3, 10) for both
L3 and Y . The notation D¯ means “conditional on the data that has already been measured (generated)
according the the time ordering”.
For t = 0:
V 1 ∼ B(p = 4392/5826)
V 2|D¯ ∼
{
B(p = 2222/4392) if V 1 = 1
B(p = 758/1434) if V 1 = 0
V 3|D¯ ∼ U(1, 5)
L10|D¯ ∼
{
N[0,10000](650, 350) if V
1 = 1
N[0,10000](720, 400)) if V
1 = 0
L˜10|D¯ ∼ N((L10 − 671.7468)/(10 · 352.2788) + 1, 0)
L20|D¯ ∼ N[0.06,0.8](0.16 + 0.05 · (L10 − 650)/650, 0.07)
L˜20|D¯ ∼ N((L20 − 0.1648594)/(10 · 0.06980332) + 1, 0)
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L30|D¯ ∼
{
N[−5,5](−1.65 + 0.1 · V 3 + 0.05 · (L10 − 650)/650 + 0.05 · (L20 − 16)/16, 1) if V 1 = 1
N[−5,5](−2.05 + 0.1 · V 3 + 0.05 · (L10 − 650)/650 + 0.05 · (L20 − 16)/16, 1)) if V 1 = 0
A0|D¯ ∼ B(p = 0)
C0|D¯ ∼ B(p = 0)
Y0|D¯ ∼ N[−5,5](−2.6 + 0.1 · I(V 3 > 2) + 0.3 · I(V 1 = 0) + (L30 + 1.45), 1.1)
For t > 0:
L1t |D¯ ∼

N[0,10000](13 · log(t · (1034− 662)/8) + L1t−1 + 2 · L2t−1 + 2 · L3t−1 + 2.5 ·At−1, 50) if t ∈ {1, 2, 3, 4}
N[0,10000](4 · log(t · (1034− 662)/8) + L1t−1 + 2 · L2t−1 + 2 · L3t−1 + 2.5 ·At−1, 50) if t ∈ {5, 6, 7, 8}
N[0,10000](L
1
t−1 + 2 · L2t−1 + 2 · L3t−1 + 2.5 ·At−1, 50) if t ∈ {9, 10, 11, 12}
L2t |D¯ ∼ N[0.06,0.8](L2t−1 + 0.0003 · (L1t − L1t−1) + 0.0005 · (L3t−1) + 0.0005 ·At−1 · L˜10, 0.02)
L3t |D¯ ∼ N−5,5(L3t−1 + 0.0017 · (L1t − L1t−1) + 0.2 · (L2t − L2t−1) + 0.005 ·At−1 · L˜20, 0.5)
At|D¯ ∼
{
B(p = 1) if At−1 = 1
B(p = 1/(1 + exp(−[−2.4 + 0.015 · (750− L1t ) + 5 · (0.2− L2t )− 0.8 · L3t + 0.8 · t]))) if At−1 = 0
Ct|D¯ ∼ B(p = 1/(1 + exp(−[−6 + 0.01 · (750− L1t ) + 1 · (0.2− L2t )− 0.65 · L3t −At])))
Yt|D¯ ∼ N[−5,5](Yt−1 + 0.00005 · (L1t − L1t−1)− 0.000001 ·
(
(L1t − L1t−1) ·
√
L˜10
)2
+ 0.01 · (L2t − L2t−1)−
0.0001 ·
(
(L2t − L2t−1) ·
√
L˜20
)2
+ 0.07 · ((L3t − L3t−1) · (L30 + 1.5135))− 0.001 · ((L3t − L3t−1) · (L30 + 1.5135))2 +
0.005 ·At + 0.075 ·At−1 + 0.05 ·A[t] ·A[t− 1], 0.01)
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